Beam Therapeutics reported promising Phase 1/2 data for BEAM-302, demonstrating durable gene correction for AATD. See why I ...

EDT Cathie Wood’s ARK Investment buys 143K shares of Beam Therapeutics (BEAM) todayLight Up your Portfolio with Spark:Easily identify ...

We recently published a list of 10 Best Growth Stocks to Invest in for the Next 10 Years. In this article, we are going to ...

Research analysts at Leerink Partnrs lifted their Q1 2025 earnings estimates for shares of Beam Therapeutics in a research ...

Cathie Wood-led Ark Invest made notable trades, buying IRDM, BEAM, PACB, ABSI and selling ILMN, RPTX, AMGN, VEEV.

Investors and market watchers keenly observe ARK’s daily trades, as Cathie Wood’s ETFs are known for their active management and focus on disruptive innovation. The trades provide insights into the ...

While initial study results suggest Beam's technology can correct alpha-1 antitrypsin deficiency's genetic roots, shares fell by double digits.

In this article, we are going to take a look at where Beam Therapeutics Inc. (NASDAQ:BEAM) stands against other best growth stocks to invest in for the next 10 years. On March 8, Ben Snider ...

Citi raised the firm’s price target on Beam Therapeutics (BEAM) to $64 from $56 and keeps a Buy rating on the shares. With positive BEAM-302 ...

Fintel reports that on March 10, 2025, Scotiabank upgraded their outlook for Beam Therapeutics (NasdaqGS:BEAM) from Sector Perform to Sector Outperform. Analyst Price Forecast Suggests 92.72% ...